

Artwork Proof Box:		Technical Colours:	
Variation:	001 - Initial application - Mock ups for National Phase		Legend:
Proof no:	001.3		Cutting:
Date prepared:	19/06/2023		
Font size:	8.5 pt		
Fonts:	FuturaCEEf		
Dimensions:	80 x 192 mm		
Technical data:			
SKUs:	00000000		
SZ codes:	SZ0000000000		
Item codes:	00000000	Colours:	
Pharma codes:	00000000		Pantone 541
Novartis data if applicable:			
Version:	00000000		
Print Proof date:	00000000		
AQWA#:	00000000		
Production site:	00000000		
Technical num:	00000000		
Old Comp num:	00000000		

Signature Panel:

80 mm

192 mm

abnormal menstrual flow or vaginal bleeding, blood in the urine which may be pink or brown, red/black stools, coughing up blood, vomiting blood or coffee ground like material.

- In case of fall or injury, especially if the head is hit, urgently seek medical advice.
- Do not stop intake of Dabigatran etexilate without talking to your / your child's doctor, if you / your child experience(s) heartburn, nausea, vomiting, stomach discomfort, bloating or upper abdominal pain.

Dabigatran etexilate Information for Healthcare Professionals

- Dabigatran etexilate is an oral anticoagulant (direct thrombin inhibitor).
- Dabigatran etexilate may need to be stopped in advance of surgical or other invasive procedures.
- In case of major bleeding events, Dabigatran etexilate must be stopped immediately.
- A specific reversal agent (idarucizumab) is available for adult patients. The efficacy and safety of the specific reversal agent idarucizumab have not been established in paediatric patients

For details and more advice to antagonise the anticoagulant effect of Dabigatran etexilate please refer to the Summary of Product Characteristics of Dabigatran etexilate and idarucizumab.

Dabigatran etexilate is mainly eliminated by the kidneys; adequate diuresis must be maintained. Dabigatran etexilate is dialysable.

Please complete this section or ask your / your child's doctor to do it.

Patient Information


Name of the patient _____

Date of birth _____




Indication for anticoagulation _____


Dose of Dabigatran etexilate _____

Date of Revision : Mar 2023



XXXXXXXXXX

Artwork Proof Box:		Technical Colours:	
Variation:	001 - Licence app		Legend:
Proof no:	001.0		Cutting:
Date prepared:	08/02/2023		
Font size:	8.5 pt		
Fonts:	FuturaCEEFF		
Dimensions:	80 x 192 mm		
Technical data:			
SKUs:	00000000		
SZ codes:	SZ0000000000		
Item codes:	00000000		
Pharma codes:	00000000		Pantone 541
Novartis data if applicable:			
Version:	00000000		
Print Proof date:	00000000		
AQWA#:	00000000		
Production site:	00000000		
Technical num:	00000000		
Old Comp num:	00000000		



Signature Panel:	